Solve ME/CFS Initiative

New Video! The fourth and final webinar in the Solve M.E. and Bateman Horne Center of Excellence “Severe ME/CFS: Care, Rights, and Research” series focuses on Severe ME/CFS research.? Watch? the recording of “Severe ME/CFS Research: Removing Barriers to Access” here: https://lnkd.in/gi_XCDEP Because traditional research methods are not always accessible to the severely ill, people with severe ME/CFS are often missing from clinical research. As they make up nearly 25% of all people with ME/CFS, their absence greatly limits our understanding of the disease. Those with lived experience have fought to change exclusionary research study models and reduce the many barriers to access. Solve CEO Emily Taylor talks to Sabrina Poirier (co-founder of the ICanCME Research Network) and Dr. David Putrino (Department of Rehabilitation and Human Performance at the Icahn School of Medicine at Mount Sinai) about how patients are working with researchers to increase research accessibility from concept to real-world execution.

Read our summary of a new Solve-funded study by Dr. Deborah Duricka and Dr. Luke Liu (Neuroversion) testing how much Stellate Ganglion Block reduced symptoms in people who had?both?Long Covid and ME/CFS.?

People with Long Covid may participate in an important new clinical trial—the REVERSE-LC trial (Evaluating Baricitinib on Persistent Neurologic and Cardiopulmonary Symptoms of Long COVID)—which will test whether the drug baricitinib improves neurocognitive function and other functions severely diminished by Long Covid. Dr. Wesley Ely, an internationally respected pulmonologist and critical care doctor at Vanderbilt University Medical Center, is leading this trial. Baricitinib was the first immunomodulating drug approved for patients with acute COVID. The overall goal of the REVERSE-LC trial will be to determine how much baricitinib improves neurocognitive function in patients with Long Covid. The team is now recruiting 550 patients from the continental US to participate. The team will financially compensate participants for their time and will pay for hotel accommodation during on-site visits. For more information on enrolling in the REVERSE-LC trial, people should contact Ms. Amy Bazzoni (615-343-8010, [email protected]). For more details, read our blog post here: https://lnkd.in/daaitixg

ICYMI: Read commentary from AIM ImmunoTech on the recent JGIM Journal of General Internal Medicine publication linking ME/CFS & Long Covid and how those findings support the development of Ampligen as a potential therapeutic. https://lnkd.in/gPHqbpcm

Solve M.E. and Simmaron Research Inc.-funded research finds new animal models to study ME/CFS–related muscle fatigue and #PEM. The study helped identify the FDA-approved drug rapamycin as a treatment candidate and launched a multi-site treatment trial. Dr. Avik Roy—chief scientific officer at Simmaron and professor at the University of Wisconsin–Milwaukee—co-authored with Gunnar Gottschalk and others the study, “Inactivation of ATG13 stimulates chronic demyelinating pathologies in muscle-serving nerves and spinal cord,” published in the journal Immunologic Research. Solve M.E. has long supported Dr. Avik Roy’s important work,?awarding Dr. Roy a Ramsay Research Grant?in 2022. Read our summary of “Inactivation of ATG13 stimulates chronic demyelinating pathologies in muscle-serving nerves and spinal cord” here: ow.ly/N1z950UMfU7

ICYMI: Solve-funded researcher Dr. Rob Wüst recently published a piece in Trends in Endocrinology and Metabolism about how changes in the muscles of patients with Long Covid relate to post-exertional malaise (PEM). Read our summary of the publication here.

Solve will be represented by H. Timothy Hsiao, PhD, at the upcoming PMWC - Precision Medicine World Conference in Silicon Valley Feb. 5-7. He'll be presenting “Catalyzing a RWD Strategic Alliance for Precision Medicine” as part of the AI and Data Sciences Showcase.?Tim will discuss Solve M.E.'s real-world data (RWD) platform, Solve Together, with case studies on how the platform helped explore IACCI patient subtyping and trial recruitment, and also discuss the vision to catalyze a RWD strategic alliance to advance IACCI precision medicine. Tim will be joining leading experts to explore key topics such as gene and cell therapies, AI-driven drug discovery, liquid biopsies, cutting-edge multi-omics approaches, real-world evidence, women’s health innovations, clinical metagenomics, pharmacogenomics, and emerging diagnostics. #PMWC25 Learn more about the conference here:?https://lnkd.in/dk2yvMDy

Starting soon! The final event in our webinar series with Bateman Horne Center of Excellence "Severe #MECFS Research: Removing Barriers to Access" starts at 10 am PT / 1 pm ET today. Solve CEO Emily Taylor will host Dr, David Putrino and Sabrina Poirier to discuss how people with lived experience are working with researchers to increase research accessibility from concept to real-world execution. Sign up now! https://lnkd.in/gEwqFAv3

The Solve M.E.-Bateman Horne Center of Excellence webinar “Severe ME/CFS Research: Removing Barriers to Access” has been rescheduled for Tuesday, January 21st at 10 am PT. Because traditional research methods are not always accessible to the severely ill, people with severe ME are often missing from clinical research. As they make up nearly 25% of all people with ME/CFS, their absence greatly limits our understanding of the disease. Those with lived experience have fought to change exclusionary research study models and reduce the many barriers to access. Solve M.E. CEO Emily Taylor hosts Sabrina Poirier (co-founder of the ICanCME Research Network) and David Putrino (Department of Rehabilitation and Human Performance at the Icahn School of Medicine at Mount Sinai) to discuss how patients are working with researchers to increase research accessibility from concept to real-world execution. Register here: https://lnkd.in/gEwqFAv3

An important new study finds cases of ME/CFS increase following SARS-CoV-2. Read our summary of the study published in JGIM Journal of General Internal Medicine and co-authored by Solve CEO Emily Taylor here: